|
1
|
Kilcline C and Frieden IJ: Infantile
hemangiomas: how common are they? A systematic review of the
medical literature. Pediatr Dermatol. 25:168–173. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen TS, Eichenfield LF and Friedlander
SF: Infantile hemangiomas: an update on pathogenesis and therapy.
Pediatrics. 131:99–108. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Castaneda S, Melendez-Lopez S, Garcia E,
De la Cruz H and Sanchez-Palacio J: The role of the pharmacist in
the treatment of patients with infantile hemangiomas using
propranolol. Adv Ther. 33:1831–1839. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Khorsand K, Backus S and Sidbury R: What's
new in pediatric dermatology. Current Dermatology Reports.
3:187–190. 2014. View Article : Google Scholar
|
|
5
|
Long CL, Jeevanandam M and Kinney JM:
Metabolism and recycling of urea in man. Am J Clin Nutr.
31:1367–1382. 1978.PubMed/NCBI
|
|
6
|
Fredriksson T and Gip L: Urea creams in
the treatment of dry skin and hand dermatitis. Int J Dermatol.
14:442–444. 1975. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Li G and Gu J: Infantile Hemangioma. 1st.
Shaanxi Science and Technology Press; Xian: 1991, (In Chinese).
|
|
8
|
Liang X, Dong C, Ma Y, Lei H, Liu D, Qiao
J and Xiao L: The treatment of spongy infantile hemangioma on body
surface by local urea injection. Chin Hosp Pharm J. 31:1396–1397.
2011.(In Chinese).
|
|
9
|
Chang Y, Dong C and Zheng W: The clinical
observation of 80 cases of infantile hemangioma by urea local
injection. Clin Med. 19:52–53. 1999.(In Chinese).
|
|
10
|
Lei H, Huang J, Meng X, Zhang W, Dong C,
Sun B and Ma Y: Carbonyldiamide injection therapy for 167 cases of
infant hemangiomas at peculiar region. J Medical Forum. 35:3–5.
2014.(In Chinese).
|
|
11
|
Guo X, Zhu X, Dong C and Ma Y: Clinical
analysis of 32 cases of vulvar sponge hemangioma receiving
intratumoral urea injection combined with surgery. Chin J Obstet
Gynecol. 50:221–223. 2015.(In Chinese).
|
|
12
|
Müller-Goymann CC: Physicochemical
characterization of colloidal drug delivery systems such as reverse
micelles, vesicles, liquid crystals and nanoparticles for topical
administration. Eur J Pharm Biopharm. 58:343–356. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Almeida H, Amaral MH, Lobao P, Frigerio C
and Lobo JM Sousa: Nanoparticles in ocular drug delivery systems
for topical administration: promises and challenges. Curr Pharm
Des. 21:5212–5224. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Freiberg S and Zhu XX: Polymer
microspheres for controlled drug release. Int J Pharm. 282:1–18.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gao J, Xia Y, Chen H, Yu Y, Song J, Li W,
Qian W, Wang H, Dai J and Guo Y: Polymer-lipid hybrid nanoparticles
conjugated anti-EGFR antibody for targeted drug delivery to
hepatocellular carcinoma. Nanomedicine (Lond). 9:279–293. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Van Slooten ML, Boerman O, Romøren K,
Kedar E, Crommelin DJ and Storm G: Liposomes as sustained release
system for human interferon-gamma: biopharmaceutical aspects.
Biochim Biophys Acta. 1530:134–145. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Xiao C, Qi X, Maitani Y and Nagai T:
Sustained release of cisplatin from multivesicular liposomes:
potentiation of antitumor efficacy against S180 murine carcinoma. J
Pharm Sci. 93:1718–1724. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bittman R and Clejan S: Kinetics of
cholesterol and phospholipid exchange between mycoplasma membranes
and lipid vesicles. Isr J Med Sci. 23:398–402. 1987.PubMed/NCBI
|
|
19
|
New RRC: Liposomes: A Practical Approach.
Publisher: Oxford University Press; Revised edition. 1990
|
|
20
|
Shive MS and Anderson JM: Biodegradation
and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv
Rev. 28:5–24. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Dass CR, Walker TL, Kalle WH and Burton
MA: A microsphere-liposome (microplex) vector for targeted gene
therapy of cancer. II. In vivo biodistribution study in a solid
tumor model. Drug Deliv. 7:15–9. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Feng SS, Ruan G and Li QT: Fabrication and
characterizations of a novel drug delivery device
liposomes-in-microspheres (LIM). Biomaterials. 25:5181–5189. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Medici D and Olsen BR: Rapamycin inhibits
proliferation of hemangioma endothelial cells by reducing
HIF-1-dependent expression of VEGF. PLoS One. 7:e429132012.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Shuming C, Shaoquan C, Zaizhong Z,
Chengjin L, Yin X, Chen L, Qingjin H and Lie W: Effects of topical
rapamycin hydrochloride gel for treatment of infantile hemangiomas
in nude mice). Zhonghua Zheng Xing Wai Ke Za Zhi. 31:446–450.
2015.(In Chinese). PubMed/NCBI
|
|
25
|
Wang Z, Li J, Xu X, Duan X and Cao G: Urea
immunoliposome inhibits human vascular endothelial cell
proliferation for hemangioma treatment. World J Surg Oncol.
11:3002013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Greenberger S, Yuan S, Walsh LA, Boscolo
E, Kang KT, Matthews B, Mulliken JB and Bischoff J: Rapamycin
suppresses self-renewal and vasculogenic potential of stem cells
isolated from infantile hemangioma. J Invest Dermatol.
131:2467–2476. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Mason JC, Lidington EA, Ahmad SR and
Haskard DO: bFGF and VEGF synergistically enhance endothelial
cytoprotection via decay-accelerating factor induction. Am J
Physiol Cell Physiol. 282:578–587. 2002. View Article : Google Scholar
|
|
28
|
Manalo DJ, Rowan A, Lavoie T, Natarajan L,
Kelly BD, Ye SQ, Garcia JG and Semenza GL: Transcriptional
regulation of vascular endothelial cell responses to hypoxia by
HIF-1. Blood. 105:659–669. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Déry MA, Michaud MD and Richard DE:
Hypoxia-inducible factor 1: regulation by hypoxic and non-hypoxic
activators. Int J Biochem Cell Biol. 37:535–540. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Li P, Guo Z, Gao Y and Pan W: Propranolol
represses infantile hemangioma cell growth through the
β2-adrenergic receptor in a HIF-1α-dependent manner. Oncol Rep.
33:3099–3107. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Nystrom AM and Fadeel B: Safety assessment
of nanomaterials: implications for nanomedicine. J Control Release.
161:403–408. 2012. View Article : Google Scholar : PubMed/NCBI
|
